FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
GALLISPAT Share Price Discussion
Gallantt Ispat Ltd.
Sector: Iron and Steel
Sector: Iron and Steel
Find answers to all your questions on live GALLISPAT message board: Is GALLISPAT buy or sell? Should I buy GALLISPAT shares? Why are GALLISPAT shares falling? Should I invest in GALLISPAT stock?
@newsbot • Reputation: 1,933
GSK Pharma Q2 profit at Rs 503 cr
Revenue from operations stood at Rs 882.02 crore for the quarter under review as against Rs 816.31 crore in the same period a year ago.
Revenue from operations stood at Rs 882.02 crore for the quarter under review as against Rs 816.31 crore in the same period a year ago.
Moneycontrol
Like
reply
Reply
Recent posts in GALLISPAT
@newsbot • Reputation: 1,933
GlaxoSmithKline Consolidated September 2019 Net Sales at Rs 882.02 crore, up 0% Y-o-Y
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,933
GSK Pharma slips 5% after halting sale of acidity medicine Zinetac, other ranitidine products
The company has made the decision to initiate a voluntary recall of Zinetac Tablets 150 mg and 300 mg products manufactured in India.
The company has made the decision to initiate a voluntary recall of Zinetac Tablets 150 mg and 300 mg products manufactured in India.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,933
Government scrambles to address shortage of rabies vaccine after GSK exit
Sources within the vaccine industry said that one of the main reasons for the current shortage was due to the exit of Chiron Behring Vaccines, a unit of GlaxoSmithKline (GSK).
Sources within the vaccine industry said that one of the main reasons for the current shortage was due to the exit of Chiron Behring Vaccines, a unit of GlaxoSmithKline (GSK).
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,933
Focus on selective products, therapies starting to pay dividends: GSK Pharma
Vaidheesh hinted at new launches such as a vaccine (Bexsero) to protect infants against Meningitis B and a new drug to treat autoimmune disorders
Vaidheesh hinted at new launches such as a vaccine (Bexsero) to protect infants against Meningitis B and a new drug to treat autoimmune disorders
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,933
Hold GlaxoSmithKline Consumer Healthcare; target of Rs 7972: Prabhudas Lilladher
Prabhudas Lilladher recommended hold rating on GlaxoSmithKline Consumer Healthcare with a target price of Rs 7972 in its research report dated August 05, 2019.
Prabhudas Lilladher recommended hold rating on GlaxoSmithKline Consumer Healthcare with a target price of Rs 7972 in its research report dated August 05, 2019.
moneycontrol.com
Like
reply
Reply